Kymera Therapeutics
KYMR
128 hedge funds and large institutions have $2.76B invested in Kymera Therapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 13 closing their positions.
2,902% more call options, than puts
Call options by funds: $8.82M | Put options by funds: $294K
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
93% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 28
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
36% more capital invested
Capital invested by funds: $2.04B → $2.76B (+$724M)
16.74% more ownership
Funds ownership: 67.86% → 84.6% (+17%)
11% more funds holding
Funds holding: 115 → 128 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$34.9M |
| 2 |
BlackRock
New York
|
+$20.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$12M |
| 2 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$10.6M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$10.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$7.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.78M |
KYMR Hedge Fund Activity: Q4 2021 in Review
128 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2021, worth a combined $2.76B — up 36% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KYMR positions and 13 closed out — a net gain of 15 holders — while 54 added to existing stakes and 28 trimmed.
The largest buyer was Artal Group, adding an estimated $34.9M. The largest seller was Redmile Group, cutting an estimated $12M.
- 128 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2021, up from 115 in Q3 2021.
- Funds reported $2.76B of Kymera Therapeutics stock for Q4 2021, up 36% quarter-over-quarter.
- 28 funds opened new Kymera Therapeutics positions in Q4 2021 and 13 closed out, a net change of +15 holders.
- The largest Kymera Therapeutics buyer in Q4 2021 was Artal Group, an estimated $34.9M added.
- The largest Kymera Therapeutics seller in Q4 2021 was Redmile Group, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2021.